Search results
Showing 4261 to 4275 of 8907 results
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
See a complete list of all our guidance and quality standards currently open for consultation
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Next-generation sequencing panel for solid tumour cancers in children (MIB133)
NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)
NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .